Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.88 Analyst target: $3.93 Upside: 346.59%
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.
See the full interactive analysis & chart →Informational only — not investment advice.